Lodo Therapeutics Corp. (Lodo), a biotechnology company reinventing natural product drug discovery by applying its informatics-enabled technology platform to previously undruggable disease targets, today announced that it has completed the acquisition of Hibiskus BioPharma, Inc. (Hibiskus). In a related transaction, Lodo has acquired exclusive worldwide rights from the University of California, Riverside (UCR) and Michigan State University (MSU) to preclinical proteasome and immunoproteasome inhibitors developed by the co-founders of Hibiskus. Together, these two transactions enable Lodo to consolidate the proteasome inhibitor portfolio and related intellectual property, know-how and early stage research.
Read the full article: Lodo Therapeutics Acquires Hibiskus BioPharma //
Source: https://www.prnewswire.com/news-releases/lodo-therapeutics-acquires-hibiskus-biopharma-and-licenses-rights-to-novel-proteasome-inhibitors-301123605.html